Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Top US FDA Drug Policy Leader Leaving For White House Detail

Jan 26 2022

• By Derrick Gingery

White House and FDA building 21 — Elizabeth Jungman will take over Grail Sipes' advisory duties in the Center for Drug Evaluation and Research once she moves to the White House. • Source: Nielsen Hobbs; the Pink Sheet | Alamy images

Related Content

Chief Scientist At US FDA Is Hinton As Borio Moves To White House

Jun 26 2017

US FDA May Ask Congress For More Resources After Withdrawing Generic Label Reg

Dec 14 2018

FDA Broadens Nicotine Therapy Indication Review With Steering Committee Docket

Feb 16 2018

New Social Media Guidance From US FDA May Be On The Horizon

Nov 04 2020

Compounding Chief Departing US FDA After Leading Office Through 'Tumultuous Times'

Mar 22 2019

US FDA Lowers FY '22 PDUFA Fees Due to Hiring, Attrition Concerns

Aug 13 2021

Califf Clears First Senate Hurdle, But FDA Abortion Pill Decision May Complicate Final Confirmation

Jan 14 2022

FDA’s Office Of Regulatory Policy To Be Headed By Covington & Burling Alum

Sep 17 2014

Clinical Trial Network For Antibiotics Included In President’s FY 2016 Budget

Jan 28 2015

Exclusivity Period Allowed By OTC Monograph Reform Likely Up To Conference Committee

Jul 19 2018

Additional Topics

United States FDA Leadership Regulation BioPharmaceutical

More from US FDA

More from Agency Leadership

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window